1261. Vitamin D – A New Perspective in Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage
Authors: Sepide Kashefiolasl; Matthias Leisegang, PhD; Valeska Helfinger, PhD; Christoph Schürmann, PhD; Voahanginirina Randriamboavonjy, PhD; Geert Carmeliet, MD, PhD; Klaus Badenhoop, MD, PhD; Katrin Schröder, PhD; Volker Seifert, MD, PhD; Ralf Brandes, MD, PhD; Juergen Konczalla, MD, PhD (Frankfurt am Main, Germany)
Cerebral vasospasm (CVS) is a severe complication after subarachnoid hemorrhage (SAH). We explored vitamin D (VitD) as a possible therapeutic option for CVS in SAH patients.
The translational study was composed of an experimental and a clinical arm. 25-VitaminD3 (VitD3) levels tested between 2007-2015 and data of SAH patients admitted during the months with a peak versus nadir of VitD3-values were analyzed, retrospectively. Furthermore, we prospectively correlated VitD3 and vasospasm/outcome data in SAH patients admitted in 2017 after written informed consent. An experimental mice SAH model and cell culture model using 1,25-dihydroxy-VitaminD3 (1,25-VitD3) or not were used to investigate the pathophysiological differences. Additionally, the mediators acting in the VitD mechanism were researched and detected.
Patients with VitD-deficiency have a higher rate of severe CVS and worse outcome. 1,25-VitD3, by inducing SDF1α, attenuates CVS after subarachnoid hemorrhage. VitD administration should be tested as a treatment option to prevent CVS in SAH patients.